ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 4

Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

, , ,

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

Video content above is prompted by the following:

  • Briefly discuss role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.